LC
DXCM icon

Lindbrook Capital’s DexCom DXCM Stock Holding History

Lindbrook Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$129K Buy
1,882
+142
+8% +$11.6K 0.01% 571
2024
Q4 		$135K Buy
1,740
+1,239
+247% +$91.7K 0.01% 475
2024
Q3 		$33.6K Sell
501
-1,213
-71% -$99.6K ﹤0.01% 1011
2024
Q2 		$194K Sell
1,714
-41
-2% -$5.18K 0.02% 370
2024
Q1 		$243K Buy
1,755
+172
+11% +$21.6K 0.02% 318
2023
Q4 		$196K Buy
1,583
+268
+20% +$27.4K 0.02% 351
2023
Q3 		$123K Sell
1,315
-264
-17% -$29.8K 0.01% 415
2023
Q2 		$203K Buy
1,579
+1
+0.1% +$121 0.02% 322
2023
Q1 		$183K Buy
1,578
+107
+7% +$12K 0.02% 333
2022
Q4 		$167K Buy
1,471
+422
+40% +$46.3K 0.02% 370
2022
Q3 		$84K Buy
1,049
+295
+39% +$25K 0.01% 489
2022
Q2 		$56K Buy
754
+38
+5% +$3.47K 0.01% 615
2022
Q1 		$92K Sell
716
-28
-4% -$3.06K 0.01% 492
2021
Q4 		$100K Buy
744
+252
+51% +$36.2K 0.02% 491
2021
Q3 		$67K Buy
492
+28
+6% +$3.53K 0.02% 361
2021
Q2 		$50K Sell
464
-44
-9% -$4.22K 0.01% 477
2021
Q1 		$46K Buy
508
+68
+15% +$6.38K 0.01% 481
2020
Q4 		$41K Sell
440
-136
-24% -$12.1K 0.01% 461
2020
Q3 		$59K Buy
576
+112
+24% +$11.7K 0.02% 314
2020
Q2 		$47K Sell
464
-72
-13% -$6.44K 0.01% 368
2020
Q1 		$36K Buy
536
+160
+43% +$9.96K 0.01% 396
2019
Q4 		$21K Buy
376
+76
+25% +$3.6K 0.01% 721
2019
Q3 		$11K Hold
300
– – ﹤0.01% 869
2019
Q2 		$11K Sell
300
-40
-12% -$1.26K ﹤0.01% 860
2019
Q1 		$10K Buy
340
+40
+13% +$1.41K ﹤0.01% 893
2018
Q4 		$8K Buy
+300
New +$9.52K ﹤0.01% 875

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lindbrook Capital's DXCM Position: Q1 2025 in Review

Lindbrook Capital increased its DexCom (DXCM) stake by 8.2% in Q1 2025, buying an estimated $11.6K and bringing the position to 1,882 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #571.

Lindbrook Capital first reported a position in DXCM in Q4 2018 and has held it in 26 quarters since. The position peaked at $243K in Q1 2024. 933 funds tracked by Wall St. Rank hold DXCM as of Q1 2025.

  • Lindbrook Capital held 1,882 shares of DexCom worth $129K as of Q1 2025.
  • Lindbrook Capital bought 142 DexCom shares in Q1 2025, an estimated $11.6K.
  • DexCom made up 0.01% of Lindbrook Capital's portfolio in Q1 2025, its #571 holding.
  • Lindbrook Capital first reported a position in DexCom in Q4 2018 and has held it in 26 quarters since.
  • Lindbrook Capital's DexCom position peaked at $243K in Q1 2024.
  • 933 funds tracked by Wall St. Rank held DexCom as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.